论文信息 - LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC - 字舞流文

LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC

P. Jänne | Melissa L. Johnson | M. Nishio | K. Gold | H. Murakami | C. Baik | H. Hayashi | W. Su | Helena A. Yu | Shuquan Chen | C. Steuer | M. Koczywas | J.C. Yang | Z. Qi | Y. Qiu | C. Yu | S. Karam | H. Yu | M. Johnson